-
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
•
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in a Series D++ financing round, co-led by a globally renowned industry investment institution and a prominent insurance fund. The funds raised will be directed towards the commercialization of its core product, senaparib, a PARP1 inhibitor,…
-
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
•
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD 55.2 million) in a Series D+ financing round. The round was co-led by GTJA Investment and KingRay Capital, a state-owned investor focused on small and micro enterprises. Additional participants in the financing round included Guojin…
-
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service agreement with domestic firm Impact Therapeutics, securing exclusive market promotion rights for Impact’s senaparib in mainland China. Under the agreement, Huadong will pay an initial fee of RMB 100 million (USD 14 million) and is…
